Skip to main content
Top
Published in: Diabetologia 3/2007

01-03-2007 | Article

Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy—a nationwide 5-year-study in Japan

Authors: Y. Murase, A. Imagawa, T. Hanafusa, H. Iwahashi, Y. Uchigata, A. Kanatsuka, E. Kawasaki, T. Kobayashi, A. Shimada, I. Shimizu, T. Maruyama, H. Makino

Published in: Diabetologia | Issue 3/2007

Login to get access

Abstract

Aims/hypothesis

The aim of the present study was to assess the development of microangiopathy in patients with fulminant type 1 diabetes, a novel subtype of type 1B diabetes.

Materials and methods

In a nationwide survey, we followed 41 patients with fulminant type 1 diabetes and 76 age- and sex-matched patients with type 1A diabetes for 5 years. The following data were recorded every 12 months after the onset of diabetes: seven-point blood glucose concentrations, HbA1c level, urinary albumin excretion, serum C-peptide level, blood pressure, daily dosages of insulin, frequency of severe hypoglycaemic episodes, and neurological and fundoscopic examination.

Results

The 5-year cumulative incidence of microangiopathy was 24.4% in fulminant type 1 diabetes and 2.6% in type 1A diabetes. In longitudinal studies using the Kaplan–Meier method, the cumulative incidence of each form of microangiopathy was significantly higher in fulminant type 1 diabetes than in type 1A diabetes; retinopathy was 9.8% vs 0% (p = 0.014), nephropathy 12.2% vs 2.6% (p = 0.015) and neuropathy 12.2% vs 1.3% (p = 0.010), respectively. Mean HbA1c levels were similar in the fulminant and type 1A diabetes groups during the follow-up periods. However, the mean M-value, mean insulin dosages and the frequency of severe hypoglycaemic episodes were significantly higher, and the mean postprandial C-peptide level was significantly lower in the fulminant type 1 diabetes group.

Conclusions/interpretation

These data suggest that patients with fulminant type 1 diabetes are a high-risk subgroup for diabetic microangiopathy associated with the lack of endogenous insulin secretion from the onset of diabetes.
Literature
1.
go back to reference The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197
2.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
3.
go back to reference Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307PubMedCrossRef Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307PubMedCrossRef
4.
go back to reference Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352PubMed Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352PubMed
5.
go back to reference Shimizu I, Makino H, Imagawa A et al (2006) Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91:471–476PubMedCrossRef Shimizu I, Makino H, Imagawa A et al (2006) Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91:471–476PubMedCrossRef
6.
go back to reference Imagawa A, Hanafusa T, Uchigata Y et al (2005) Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48:294–300PubMedCrossRef Imagawa A, Hanafusa T, Uchigata Y et al (2005) Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48:294–300PubMedCrossRef
7.
go back to reference Kent LA, Gill GV, Williams G (1994) Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet 344:778–781PubMedCrossRef Kent LA, Gill GV, Williams G (1994) Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet 344:778–781PubMedCrossRef
8.
go back to reference Matsumoto A, Iwashima Y, Abiko A et al (2000) Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 50:195–202PubMedCrossRef Matsumoto A, Iwashima Y, Abiko A et al (2000) Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 50:195–202PubMedCrossRef
9.
go back to reference Klein R, Klein BEK, Magli YL, Brothers RJ, Meuer SM, Davis MD (1986) An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183–1187PubMed Klein R, Klein BEK, Magli YL, Brothers RJ, Meuer SM, Davis MD (1986) An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183–1187PubMed
10.
go back to reference Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237–243PubMed Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237–243PubMed
11.
go back to reference Henricsson M, Nystrom L, Blohme G et al (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:349–354PubMed Henricsson M, Nystrom L, Blohme G et al (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26:349–354PubMed
12.
go back to reference American Diabetes Association (2004) Nephropathy in diabetes (position statement). Diabetes Care 27(Suppl 1):S79–S83 American Diabetes Association (2004) Nephropathy in diabetes (position statement). Diabetes Care 27(Suppl 1):S79–S83
13.
go back to reference Shima K, Endo J, Oimomi M, Oshima I, Omori Y, Katayama Y (1994) Inter-laboratory difference in HbA1c measurement in Japan. A report of the Committee on an inter-laboratory standarization of HbA1c determination, the Japan Diabetes Society. J Jpn Diabetes Soc 37:855–864 (in Japanese) Shima K, Endo J, Oimomi M, Oshima I, Omori Y, Katayama Y (1994) Inter-laboratory difference in HbA1c measurement in Japan. A report of the Committee on an inter-laboratory standarization of HbA1c determination, the Japan Diabetes Society. J Jpn Diabetes Soc 37:855–864 (in Japanese)
14.
go back to reference Roberts WL, Calcote CB, Cook CB et al (1998) Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 273:21–33PubMedCrossRef Roberts WL, Calcote CB, Cook CB et al (1998) Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 273:21–33PubMedCrossRef
15.
go back to reference Schlichtkrull J, Munch O, Jersild M (1954) The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 177:95–102CrossRef Schlichtkrull J, Munch O, Jersild M (1954) The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 177:95–102CrossRef
16.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
17.
go back to reference Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561–568 Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561–568
18.
go back to reference Fukuda M, Tanaka A, Tahara Y et al (1988) Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37:81–88PubMed Fukuda M, Tanaka A, Tahara Y et al (1988) Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37:81–88PubMed
19.
go back to reference The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523 The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517–523
20.
go back to reference Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K (1995) Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334–1339PubMed Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K (1995) Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334–1339PubMed
21.
go back to reference Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832–836PubMed Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832–836PubMed
22.
go back to reference Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53:250–264PubMed Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53:250–264PubMed
23.
go back to reference Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and nerve dysfunction in diabetic rats by C-peptide. Science 277:563–566PubMedCrossRef Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and nerve dysfunction in diabetic rats by C-peptide. Science 277:563–566PubMedCrossRef
24.
go back to reference Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181–189PubMedCrossRef Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181–189PubMedCrossRef
25.
go back to reference Matsumoto S, Okitsu T, Iwanaga Y et al (2005) Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 365:1642–1644PubMedCrossRef Matsumoto S, Okitsu T, Iwanaga Y et al (2005) Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 365:1642–1644PubMedCrossRef
Metadata
Title
Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy—a nationwide 5-year-study in Japan
Authors
Y. Murase
A. Imagawa
T. Hanafusa
H. Iwahashi
Y. Uchigata
A. Kanatsuka
E. Kawasaki
T. Kobayashi
A. Shimada
I. Shimizu
T. Maruyama
H. Makino
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0575-y

Other articles of this Issue 3/2007

Diabetologia 3/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.